Pay in 4 interest-free payments of $5.99 Learn more
Ships within 48 hours · Estimated delivery Sep 12 - Sep 17
The FDA subsequently classified AOD-9604 within Category 2 of the bulk drug substance review process, and the compound was later withdrawn from that nomination in April 2026
"Intranasal delivery of biologics to the central nervous system." Advanced Drug Delivery Reviews , 64(7), 614-628
The parent compound Epithalon (AEDG) lacks the protective end-modifications
Hypothyroid patients encoding combined MCT10 and DIO2 gene polymorphisms may prefer L-T3 + L-T4 combination treatment - data using a blind, randomized, clinical study
Makes skin brighter, smoother and firmer
For years, many of these peptides have existed in a regulatory gray zone, widely prescribed by integrative and functional medicine providers while their official status remained unresolved
